IPSEN, OOO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.

Completed

Conditions: Prostate Cancer

Interventions: Drug: Gonadotropin-releasing Hormone (GnRH) agonist therapy

First Posted Date: 2015-12-15

Last Posted Date: 2023-05-12

Lead Sponsor: Ipsen

Target Recruit Count: 1000

Registration Number: NCT02630641

Locations: 🇫🇷
Ipsen Central Contact, Paris, France

Eziclen Drug Utilisation in Real Life Setting

Completed

Conditions: Bowel Cleansing

Interventions: Drug: Eziclen®/Izinova®

First Posted Date: 2015-12-15

Last Posted Date: 2019-01-07

Lead Sponsor: Ipsen

Target Recruit Count: 1286

Registration Number: NCT02630680

Locations: 🇨🇿
Ustredni vojenska nemocnice, Praha, Czechia
🇩🇪
Gemeinschaftspraxis Dres. Klausmann, Aschaffenburg, Germany
🇨🇿
Krajská zdravotní, a.s., nemocnice Teplice, Teplice, Czechia

and more 13 locations

Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs

Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumors

Interventions: Other: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.

First Posted Date: 2015-12-15

Last Posted Date: 2021-12-07

Lead Sponsor: Ipsen

Target Recruit Count: 404

Registration Number: NCT02630654

Locations: 🇱🇻
Riga East University Hospital, Riga, Latvia
🇪🇪
North Estonia Medical Center, Tallinn, Estonia
🇱🇻
Pauls Stradins Clinical University Hospital, Riga, Latvia

and more 6 locations

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Phase 1

Terminated

Conditions: Neuroendocrine Tumors

Interventions: Drug: Satoreotide tetraxetan
Other: Amino acid solution
Other: Antiemetic

First Posted Date: 2015-10-30

Last Posted Date: 2023-07-19

Lead Sponsor: Ipsen

Target Recruit Count: 40

Registration Number: NCT02592707

Locations: 🇺🇸
MD Anderson Cancer Center, Department of Nuclear Medicine, Houston, Texas, United States
🇦🇺
Peter MacCallum Cancer Centre, Molecular Imaging and Targeted Therapeutics Laboratory, East Melbourne, Australia
🇦🇺
Ramsay Hollywood Private Hospital, Department of Nuclear Medicine, Perth, Australia

and more 6 locations

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: nal-IRI
Drug: 5 fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2015-09-16

Last Posted Date: 2022-10-10

Lead Sponsor: Ipsen

Target Recruit Count: 56

Registration Number: NCT02551991

Locations: 🇪🇸
Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain
🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain

and more 33 locations

Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues

Completed

Conditions: Prostate Cancer

First Posted Date: 2015-09-07

Last Posted Date: 2018-12-21

Lead Sponsor: Ipsen

Target Recruit Count: 470

Registration Number: NCT02542501

Locations: 🇵🇹
Hospital Universitário de Coimbra, Coimbra, Portugal
🇵🇹
Hospital de São José, Lisboa, Portugal
🇵🇹
Hospital de Santa Maria, Lisboa, Portugal

and more 29 locations

Validation Study of the SAGIT® Instrument in Acromegaly

Completed

Conditions: Acromegaly

First Posted Date: 2015-09-03

Last Posted Date: 2018-11-01

Lead Sponsor: Ipsen

Target Recruit Count: 227

Registration Number: NCT02539927

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
The Emory Pituitary Center, Atlanta, Georgia, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 25 locations

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

Phase 3

Completed

Conditions: Glabellar Lines

Interventions: Drug: Placebo
Biological: Botulinum toxin type A

First Posted Date: 2015-07-10

Last Posted Date: 2022-09-28

Lead Sponsor: Ipsen

Target Recruit Count: 600

Registration Number: NCT02493946

Locations: 🇫🇷
Clinique Iéna, Paris, France
🇫🇷
CHRU Hôpital, Besançon cedex, France
🇩🇪
Medical Skin Center, Düsseldorf, Germany

and more 20 locations

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Phase 3

Completed

Conditions: Acromegaly

Interventions: Drug: Lanreotide Autogel®
Drug: Lanreotide Acetate

First Posted Date: 2015-07-09

Last Posted Date: 2019-01-29

Lead Sponsor: Ipsen

Target Recruit Count: 128

Registration Number: NCT02493517

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, China
🇨🇳
Fujian Provincial Hospital, Fuzhou, China

and more 7 locations

Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice

Completed

Conditions: Upper Limb Spasticity

First Posted Date: 2015-05-27

Last Posted Date: 2019-08-05

Lead Sponsor: Ipsen

Target Recruit Count: 1004

Registration Number: NCT02454803

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇦🇹
Gaitlal-Klinik Hermagor, Hermagor, Austria
🇵🇹
Hospital Egas Moniz, Lisboa, Portugal

and more 54 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy